Barouch Lab

Science from the Dan Barouch Lab at @BIDMCHealth and @harvardmed’s Center for Virology & Vaccine Research. RTs ≠ endorsements

[Barouch Lab @BarouchLab]

New data from the Barouch Lab on BA.2.86.
1. NAb responses to BA.2.86 were lower than to BA.2 but were comparable or higher than to current circulating variants.
2. NAb titers to all variants including BA.2.86 increased following XBB infection

[Waggoner Lab @LabWaggoner]

Long COVID involves activation of proinflammatory and immune exhaustion pathways @NatImmunol @BarouchLab
https://t.co/4IyGm8HbEi

[Science Translational Medicine @ScienceTM]

Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial https://t.co/c8cVvNbdxf

[Science Translational Medicine @ScienceTM]

Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial https://t.co/c8cVvNbdxf

[Ninaad Lasrado, PhD @lasradoN]

Excited to share our work on mucosal vaccines against HPAI #H5N1 @ScienceTM @BarouchLab!! We show how mRNA and adenovirus vaccines provide protection against H5N1, with mucosal adenovirus delivery providing near complete protection!

https://t.co/hwrSULbJYy

[International Long Covid Awareness @LCawarenessInt]

Was informed @BarouchLab is still actively recruiting participants in the New England area--

#LongCovid

*Not to be used as medical advice or diagnosis. ILCA does not endorse any trial or sponsor.

[Waggoner Lab @LabWaggoner]

Mucosal delivery of a rhesus adenovirus–vectored H5N1 influenza vaccine confers protection against lethal challenge in cynomolgus macaques
https://t.co/dDseCQOPBS @ScienceTM @lasradoN @BarouchLab @harvardmed 🇺🇸

[Barouch Lab @BarouchLab]

Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)

[BIDMC Research @BIDMC_Research]

Published today in @CellCellPress: A new mRNA #TB vaccine developed at @BIDMChealth’s CVVR by @BarouchLab protected mice better than the century-old BCG shot — reducing infection, slowing spread & lowering lung bacterial levels. 🧬💉 https://t.co/kjLi8Jk47F

[Waggoner Lab @LabWaggoner]

Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines @BarouchLab @CellCellPress @BIDMChealth @harvardmed ����🇸
https://t.co/IJUKkuAIxG

[Dr. Angela Rasmussen @angie_rasmussen]

Beautiful paper from @BarouchLab looking at H5N1 pathogenesis in rhesus & cynomolgus macaques (link in replies).
Dan presented some of this work in Feb at a meeting at Scripps & the mortality data was striking. H5N1 is really pathogenic in macaques, but in species-specific ways.

[Waggoner Lab @LabWaggoner]

Mucosal delivery and gene-based vaccines can both enhance boost responses for influenza vaccination in cynomolgus macaques over available vaccines
https://t.co/vEo8VwpHJ0
@ScienceTM @BarouchLab

[Science Translational Medicine @ScienceTM]

mRNA or adenovirus flu vaccine boosters produce strong immune responses against H1N1 and match the efficacy of a live-attenuated booster in macaques, supporting their potential as a more flexible platform for #influenza vaccines. @BarouchLab @BIDMChealth https://t.co/6ATRHYQwpD

[Ninaad Lasrado, PhD @lasradoN]

#LongCovid has impaired millions of people, with no cure on the horizon. @BIDMC_CVVRTrial has launched a trial to test Abrocitinib to alleviate LC symptoms. If you’re around Boston, see if you qualify! 👇@thephysicsgirl
@ImmunoFever @EricTopol @VirusesImmunity @LCCampaign

[Barouch Lab @BarouchLab]

Email [email protected] or call 617-735-4610 to inquire. Additional information can also be found here [https://t.co/gagzfj6Zqi]. (2/2)

[Barouch Lab @BarouchLab]

Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)

[Annika Rössler, PhD @AnnikaRoessler]

I'm very excited to share our recent paper describing the antigenic relationship of SARS-CoV-2 variants in Nonhuman primates for the first time.
@BarouchLab @annetzl @lasradoN @JanineKimpel @Cambridge_Uni @MedUniInnsbruck

https://t.co/srCzL1K5SG

[Ninaad Lasrado, PhD @lasradoN]

It took some time for this to come out, but I am glad it's out now @ScienceTM!!! It was a huge effort by our team @BarouchLab @airisyc @CamilleRMazurek and many more to evaluate mucosal immune responses, 4 years into the COVID-19 pandemic.

https://t.co/4Ldsch1K3e

[JAMA @JAMA_current]

This study shows that mpox antibody responses generated by the MVA-BN vaccine wane significantly within 6 to 12 months, potentially leaving individuals vulnerable to reinfection.

https://t.co/m4tcwmrz0J

[BIDMC Research @BIDMC_Research]

New data from @BIDMChealth @BarouchLab suggests that protective immunity against #Mpox may have waned in previously vaccinated individuals and that boosting may be required to maintain robust protection

[Journal of the IAS @jiasociety]

Ahead of #HIVVaccineAwarenessDay JIAS has published a new viewpoint, “The potential of broadly neutralizing antibodies for HIV prevention”.

Read it here: https://t.co/8bq8fWrvRn #HVAD

@huubgelderblom @BarouchLab